Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Molecular Pharmaceutics|May 26, 2023
Drug Design and Success of Prospective Mouse In Vitro-In Vivo Extrapolation (IVIVE) for Predictions of Plasma Clearance (CLp) from Hepatocyte Intrinsic Clearance (CLint)Nenad Manevski, Kenichi Umehara, Neil Parrott
Clinical Pharmacology and Therapeutics|April 28, 2025
Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro DataKenichi Umehara, Neil Parrott, Andreas Günther, et al.
Clinical Pharmacology and Therapeutics|June 15, 2019
Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label RecommendationsFelix Huth, Anne Gardin, Kenichi Umehara, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 23, 2021
Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug InteractionsKenichi Umehara, Yumi Cleary, Stephen Fowler, et al.
The AAPS Journal|October 9, 2020
Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and ZidovudineLuca Docci, Kenichi Umehara, Stephan Krähenbühl, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 25, 2022
A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonistCaroline Rynn, Kenichi Umehara, Tianyi Jiang, et al.
Clinical Pharmacology and Therapeutics|July 18, 2024
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co-Administered with CYP3A4 InhibitorsKenichi Umehara, Neil Parrott, Emilie Schindler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 25, 2023
PBPK Modelling for Drugs Cleared by Non-CYP Enzymes: State-of-the-Art and Future PerspectivesAgustos C Ozbey, Stephen Fowler, Karen Leys, et al.
The AAPS Journal|August 13, 2025
Optimization of In Vitro CYP3A4 TDI Assay Conditions and Use of Derived Parameters for Clinical DDI Risk Assessment Using Static and Dynamic ModelsAlessandra Pugliano, Aynur Ekiciler, Lena Preiss, et al.
ACS Medicinal Chemistry Letters|September 15, 2022
LipMetE (Lipophilic Metabolism Efficiency) as a Simple Guide for Half-Life and Dosing Regimen Prediction of Oral DrugsGiuseppe Cecere, Laura Guasch, Andres M Olivares-Morales, et al.
Pageof 5